Marshall Wace
NGEN

Marshall Wace’s NervGen Pharma NGEN Stock Holding History

Marshall Wace’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$898K Buy
435,962
+235,603
+118% +$731K ﹤0.01% 2252
2026
Q1 		$755K Buy
+200,359
New +$868K ﹤0.01% 2269

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace's NGEN Position: Q2 2026 in Review

Marshall Wace increased its NervGen Pharma (NGEN) stake by 118% in Q2 2026, buying an estimated $731K and bringing the position to 435,962 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

Marshall Wace first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Marshall Wace held 435,962 shares of NervGen Pharma worth $898K as of Q2 2026.
  • Marshall Wace bought 235,603 NervGen Pharma shares in Q2 2026, an estimated $731K.
  • NervGen Pharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2252 holding.
  • Marshall Wace first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.